A variety of immunotherapeutic agents with differing mechanisms of action are now available for the treatment of cancer. Richard W. Joseph, MD, discusses considerations regarding switching therapy in patients who experience disease progression.
While studies have been conducted of patients placed on an anti-PD-1 therapy following disease progression on ipilimumab, Dr Joseph remarks, there is a lack of data regarding treating patients with ipilimumab following disease progression on anti-PD-1 therapy.
Among other factors, treatment toxicities need to be considered before switching therapy, he adds. “In my personal experience, I tend to see that some of the side effects that patients had from ipilimumab will be reaggravated with anti-PD-1 [therapy]. I have also seen that not happen as well,” he comments.
Dr Joseph also briefly discusses the use of combination therapy (ipilimumab and anti-PD-1 therapy), and describes how the tolerability of combination therapy further complicates the making of treatment decisions.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More